Balchem Corp (BCPC) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote today and current price chart for Balchem Corp (BCPC). It suggests using Smart Investment App from Capital.com for online trading.
Assessing Balchem (BCPC) Valuation After Recent Share Price Gains And Multi Year Returns
Balchem (BCPC) has seen recent share price gains but a month-long decline, while still showing stronger multi-year returns. Valued at $170.44, it's considered 5.2% overvalued by analysts with a fair value estimate of $162, partly due to concerns about potentially underutilized capacity and its impact on earnings growth. However, international expansion and new clinical data could challenge this cautious outlook.
Clinical study suggests Balchem's K2VITAL supports post-exercise neuromuscular signalling in older adults
A new clinical study indicates that Balchem's K2VITAL, a vitamin K2 MK-7 supplement, can improve neuromuscular signaling in adults aged 65 and over following resistance exercise. While no significant effects were seen across all participants, subgroup analysis of older adults showed enhanced nerve-muscle communication, suggesting K2VITAL may support healthy aging. Balchem highlights K2VITAL's established benefits in cardiovascular and bone health and its potential for further research in healthy aging.
BALCHEM Graham Number: $31.69 — 380% Above Median
Balchem Corp (NAS:BCPC) has a Graham Number of $31.69 as of December 2025, which is 380% above its 10-year median of 6.60. GuruFocus rates BCPC as "Fairly Valued" with a GF Score™ of 94/100, though it notes two warning signs and a Price to Graham Number ratio of 5.27, placing it worse than 91.13% of companies in the Chemicals industry. The Graham Number is a conservative valuation metric that combines asset and earnings power, but does not account for growth.
Balchem (FRA:BL9B) NonCurrent Deferred Revenue : €0.0 Mil (As of Dec. 2025)
This article reports that Balchem (FRA:BL9B) has a NonCurrent Deferred Revenue of €0.0 Mil as of December 2025. GuruFocus rates Balchem with a GF Score of 89/100 and considers it fairly valued, with a GF Value of €149.44 against a current price of €143.20. The article defines Non-Current Deferred Revenue as the non-current portion of deferred revenue where revenue has not yet been recognized and is not expected to be recognized within the next twelve months.
Vanguard (NYSE: BCPC) reports zero beneficial ownership after realignment
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Balchem Corp (BCPC) common stock. This change is a result of an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing confirms Vanguard holds no voting or dispositive power over Balchem stock as of the amendment date.
BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Balchem Corporation (BCPC) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It details recent Form 8-K filings and Form 4 insider transactions, many of which involve tax-related share withholdings by executives. The platform also offers AI-powered summaries to simplify complex sections of these regulatory documents for investors and traders.
BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Balchem Corporation (BCPC) SEC filings, including 10-K, 10-Q, and 8-K forms, offering detailed insights into the company's operations and financial performance. It highlights recent filings such as a Form 3 for an officer with zero beneficial ownership, Q3 2025 earnings showing increased net sales and net income, and shareholder approval for board elections and executive compensation. The platform also offers AI-powered summaries to help investors understand complex regulatory documents and track insider transactions.
Did Balchem's (BCPC) New Metalosate T.E.A.M. Platform Quietly Reframe Its Innovation-Led Growth Story?
Balchem Plant Nutrition recently launched Metalosate T.E.A.M., a digital platform offering micronutrient recommendations for specialty crops based on plant tissue analysis. This initiative is seen as strengthening Balchem's innovation-led growth narrative by enhancing its plant nutrition value proposition, though it doesn't immediately address concerns like tariff exposure or modest revenue growth forecasts. The platform aims to improve yield, quality, and profitability for growers while reinforcing Balchem's data-driven approach.
Did Balchem's (BCPC) New Metalosate T.E.A.M. Platform Quietly Reframe Its Innovation-Led Growth Story?
Balchem (BCPC) recently launched Metalosate T.E.A.M., a digital platform providing crop-specific micronutrient recommendations, potentially strengthening its innovation-led growth narrative. While it deepens Balchem's role in plant nutrition and data, it doesn't immediately address concerns like tariff exposure or modest revenue growth forecasts. The platform aims to enhance value proposition without altering the core debate around the company's growth, margins, and valuation, which analysts currently project at around 5.2% revenue growth and 7% earnings growth.
Balchem (BCPC) Valuation Check As Metalosate T E A M Launch Draws Fresh Investor Interest
Balchem (BCPC) recently launched its Metalosate T.E.A.M. digital platform, a tool for plant tissue analysis that provides crop-specific recommendations to advisors. Despite this innovation and the company's strong fundamentals, a valuation narrative suggests Balchem is slightly overvalued at $164, with a fair value estimated at $162. The company faces potential risks with new manufacturing facilities, but sustained demand for nutrient-dense foods could support higher future earnings.
Navigating the GLP-1 Disruption: What Future-Ready Leaders Need to Know
This webinar focuses on the impact of GLP-1 on new product innovation in the food, beverage, and supplements industries, offering strategies for manufacturers to adapt. It will cover upcoming trends like protein-forward products, solutions for muscle preservation, hydration, and nutrient gaps, as well as opportunities in functional beverages, healthy snacking, and dietary supplements. Experts from Balchem and Ernst & Young will provide market insights and highlight key areas for growth.
Balchem Corp. Experiences Valuation Adjustment Amid Competitive FMCG Landscape
Balchem Corp. has recently adjusted its valuation, now showing a P/E ratio of 34 and a price-to-book value of 3.87, along with an impressive dividend yield of 49.00%. The small-cap FMCG company's return on capital employed (ROCE) is 14.23% and return on equity (ROE) is 11.31%. When compared to competitors like The J. M. Smucker Co., Conagra Brands, Inc., Darling Ingredients, Inc., Ingredion, Inc., and Lamb Weston Holdings, Inc., Balchem's metrics position it distinctly within the sector.
Balchem Corp. Experiences Evaluation Revision Amid Mixed Market Indicators and Performance Trends
Balchem Corp. (FMCG) is currently trading at $168.36, showing mixed technical indicators with some bullish trends and neutral momentum. The stock has outperformed the S&P 500 year-to-date, with a 9.78% return against the S&P 500's -2.13%. However, its one-year performance lags behind the broader market.
Balchem Launches Metalosate TEAM As Digital Test For Crop And Valuation Narrative
Balchem Plant Nutrition has introduced Metalosate T.E.A.M., a new digital platform for specialty crops that provides plant tissue analysis and nutrient recommendations for advisors and growers. This platform aims to enhance precision crop nutrition, focusing on yield, quality, and profitability. While Balchem's shares are currently trading near their estimated fair value, the success of this initiative will depend on its adoption by agricultural advisors and its impact on the company's broader agricultural portfolio.
Balchem Corp. (NASDAQ:BCPC) Passes the 'Caviar Cruise' Quality Investing Screen
Balchem Corp. (NASDAQ:BCPC) has passed the "Caviar Cruise" quality investing screen, highlighting its strong financial health, profitability, and effective capital use. The company boasts notable debt management with a Debt-to-Free Cash Flow ratio of 0.96, high operating and profit margins, and an exceptional Return on Invested Capital (ROICexgc) of 35.60%. Its consistent growth and trustworthy earnings, evidenced by a 5-year average Free Cash Flow to Net Income ratio of 114.37% and a 13.10% EBIT increase, position it as a strong candidate for long-term investors despite its high valuation.
Balchem Launches Metalosate TEAM As Valuation And Growth Expectations Converge
Balchem (NasdaqGS:BCPC) has introduced its Metalosate T.E.A.M. digital platform, designed to provide data-driven micronutrient recommendations for plant nutrition, especially for specialty crops. This platform aims to strengthen Balchem's engagement with growers by integrating its research into daily agronomy decisions. The launch comes as Balchem's stock trades around $172.65, with analysts setting a consensus target of $200.50, and its future performance may be influenced by the adoption of this new digital tool.
Balchem Plant Nutrition Launches Digital T.E.A.M. Platform for Specialty Crops
Balchem Plant Nutrition has introduced the Metalosate® T.E.A.M.™ platform, a new free digital tool designed for pest control advisors and agronomists to optimize nutrient balance in specialty crops. This platform translates complex plant tissue data into actionable nutrition plans, aiming to improve crop profitability and quality. It also features historical data archiving for long-term nutrient tracking, helping growers avoid unnecessary applications.
Free digital tool helps specialty crops boost yield and cut costs
Balchem Plant Nutrition has launched Metalosate T.E.A.M., a free digital platform designed to provide research-driven micronutrient recommendations for specialty crops in the U.S. The platform translates plant tissue analysis into actionable insights, helping advisors optimize nutrient balance, enhance yield, and reduce input costs. This initiative follows a year of record sales and EBITDA for Balchem and aims to deepen its plant nutrition offering.
Balchem Launches Metalosate® T.E.A.M.™ Plant Tissue
Balchem Plant Nutrition has launched Metalosate® T.E.A.M.™, a digital platform for plant tissue analysis designed to provide research-driven nutrient recommendations for specialty crops. This free service helps pest control advisors and agronomists interpret complex data, optimize nutrient balance, and create actionable plans to enhance yield potential and crop quality while reducing input costs. The platform archives historical data, allowing for long-term trend tracking and informed decision-making.
Balchem (BCPC) Valuation In Focus After Recent Momentum And Mixed Total Shareholder Returns
Balchem (BCPC) shares are currently trading around $175.28, having seen a 16.47% 90-day return and a 13.80% year-to-date return, contrasting with a nearly flat 0.38% 1-year total shareholder return. Despite this recent momentum, the stock is considered "Overvalued" by Simply Wall St at $175.28 against a fair value estimate of $162, based on revenue and earnings projections. The company's new microencapsulation facility and capacity additions aim for future growth, but risks like underutilized capacity could impact margins and earnings.
Balchem (BCPC) Valuation In Focus After Recent Momentum And Mixed Total Shareholder Returns
Balchem (BCPC) shares are trading around $175.28, having shown mixed performance with strong recent momentum (16.47% in 90 days, 13.80% year-to-date) but a flat 1-year total shareholder return. The stock is considered overvalued at this price, trading above its fair value estimate of $162, despite investments in new manufacturing facilities aimed at supporting future demand. Key risks include potential underutilized capacity and the need for international expansion and clinical studies to justify premium pricing.
Balchem Corp. Experiences Revision in Its Stock Evaluation Amidst Market Dynamics
Balchem Corp., a small-cap FMCG company, has undergone a valuation adjustment, showing a P/E ratio of 34 and a price-to-book value of 3.87. The firm boasts a strong dividend yield of 49.00% and a year-to-date return of 19.50%, outperforming the S&P 500. This article details Balchem's financial metrics and compares its market perception to peers like The J. M. Smucker Co. and Conagra Brands, Inc.
Balchem Stock Lands New $18 Million Investor as Firm Delivers Record $1 Billion in Sales
Harvey Partners has acquired a new stake of 116,000 shares in Balchem Corporation, valued at $17.79 million during the fourth quarter, representing 1.6% of the fund's AUM. Balchem recently reported record 2025 results with $1 billion in net sales and $154.8 million in net earnings, showcasing strong financial performance despite its stock lagging the broader market. This investment positions Balchem as a stable addition to Harvey Partners' portfolio, emphasizing durable growth in nutrition and health over cyclical industrial trends.
Balchem Corporation stock hits 52-week high at 183.38 USD By Investing.com
Balchem Corporation's stock reached a 52-week high of $183.38. Despite this, the stock is currently trading near its 52-week high of $25.72 with a market capitalization of $5.16 billion, showing significant investor confidence and steady growth, including 16 consecutive years of dividend increases. The company also recently reported strong Q4 2025 financial results, surpassing earnings and revenue expectations.
Balchem (Nasdaq:BCPC) - Stock Analysis
This report provides a comprehensive stock analysis of Balchem (Nasdaq:BCPC), a company involved in specialty performance ingredients and products. It details the company's market overview, valuation, future growth prospects, past performance, financial health, dividend information, management, and ownership. The analysis highlights an analyst consensus target price of US$191, suggesting the stock might be undervalued, and notes expected earnings growth of 6.98% per year.
BCPC Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Balchem Corp (BCPC), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's strong profitability, steady revenue growth, low leverage, and healthy cash flow, earning it a "Safe" Altman Z-Score and a "Strong" Piotroski F-Score. The report also addresses frequently asked questions about BCPC's financial performance.
Balchem Corporation stock hits 52-week high at 183.38 USD
Balchem Corporation's stock BCPC hit a 52-week high of $183.38, indicating strong investor confidence despite currently trading around $24.81. The company has demonstrated consistent growth, raising its dividend for 16 consecutive years and reporting strong fourth-quarter 2025 financial results that exceeded analyst expectations for both EPS and revenue. InvestingPro offers further insights and 15 additional ProTips for BCPC.
Does Stronger 2025 EPS Growth Reshape the Bull Case for Balchem’s Profitability Story (BCPC)?
Balchem Corporation reported strong financial results for Q4 and full-year 2025, with increased sales, net income, and diluted EPS, reinforcing its investment thesis. Despite this, the company faces risks such as margin pressure from tariffs and new facility expansion costs. Balchem projects continued growth to $1.2 billion revenue and $203.9 million earnings by 2028, with a fair value estimate of $191.00.
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
Balchem Corporation will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent the company. Balchem specializes in manufacturing and marketing niche ingredients for global health and nutrition markets across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments.
BCPC Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Balchem Corporation (BCPC), highlighting their record Q4 2025 earnings and revenue, which exceeded expectations. It also notes the company's dividend increase and participation in significant industry conferences. Additionally, the article details Balchem's involvement with Eastman in supporting the EU's anti-dumping duties on choline chloride from China to protect the European food and feed supply chain.
Does Stronger 2025 EPS Growth Reshape the Bull Case for Balchem’s Profitability Story (BCPC)?
Balchem Corporation reported strong financial results for Q4 and full-year 2025, with increased sales, net income, and diluted EPS. This performance reinforces the company's investment narrative as a specialty ingredients provider, although risks like margin pressure from tariffs and new facility costs remain. The company's future growth hinges on sustaining this earnings momentum while managing these challenges.
Assessing Balchem (BCPC) Valuation After Strong 2025 Earnings And Share Price Gains
Balchem (BCPC) recently released strong Q4 and full-year 2025 results, with share price gains of 7.78% over 30 days and 16.62% year-to-date. Despite its current P/E ratio of 37.1x being higher than the industry average, analysts have a fair value estimate of $191, suggesting the stock is 6% undervalued. Key factors supporting future growth include a new microencapsulation facility and a strong clinical research pipeline.
Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026
Balchem Corporation (NASDAQ: BCPC) announced its participation in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will attend. Balchem is a global specialty ingredient manufacturer focusing on health and nutrition markets across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments.
Balchem Corporation to Participate in the BNP Paribas Exane
Balchem Corporation announced its participation in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent the company. Balchem is a global specialty ingredient manufacturer known for improving health and well-being across human nutrition & health, animal nutrition & health, and specialty products segments.
Health-nutrition firm Balchem to attend BNP Paribas ingredients conference
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer, announced its participation in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Key company executives, including Chairman, President & CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent Balchem at the event. This participation follows a period of significant corporate activities, including record 2025 financial performance and a dividend increase.
Balchem Corporation to Participate in the BNP Paribas Exane
Balchem Corporation announced its participation in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent the company. Balchem specializes in developing and manufacturing specialty ingredients for health and nutrition markets, with segments in Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corp. Experiences Revision in Its Stock Evaluation Amid Strong Market Position
Balchem Corp., a small-cap FMCG player, has undergone a valuation adjustment, showing strong financial metrics like a P/E ratio of 34, a 49.00% dividend yield, and competitive returns on capital and equity. These figures indicate a stronger market position compared to peers like The J. M. Smucker Co. and Conagra Brands, Inc., which have significantly lower P/E ratios. This highlights Balchem's competitive advantage within the FMCG industry.
Record 2025 growth across segments for Balchem (NASDAQ: BCPC)
Balchem Corporation reported strong financial results for both the fourth quarter and full year 2025, with record net sales, GAAP net earnings, adjusted EBITDA, and free cash flow across all segments. The company highlighted significant growth in its Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments, alongside substantial cash generation which supported share repurchases and a dividend increase. Balchem ended the year with a strong balance sheet and low net leverage, positioning it for continued future growth.
Balchem leaders to brief investors at JP Morgan consumer forum
Balchem Corporation (NASDAQ: BCPC) announced its participation in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Senior management, including CEO Ted Harris and CFO Martin Bengtsson, will attend to provide updates on their health and nutrition ingredients strategy and market positioning. The company's stock, BCPC, saw a mild positive reaction, gaining 1.64% on the day this news was published, reflecting ongoing investor engagement following strong past performance.
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
Balchem Corporation, a specialty ingredient manufacturer, announced its participation in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Key executives, including Chairman, President, and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director of Investor Relations Allison Baurichter, will represent the company. Balchem focuses on health and nutrition markets with segments in Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
Balchem Corporation announced its participation in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will attend. Balchem is a global specialty ingredient manufacturer for health and nutrition markets, with segments in Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ:BCPC) Q4 2025 Earnings Call Transcript
Balchem Corporation reported record fourth quarter and full-year 2025 financial results, with consolidated sales reaching $1.037 billion for the first time, an 8.8% increase from the prior year. The company achieved strong growth across all three segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—and delivered its 26th consecutive quarter of year-over-year adjusted EBITDA growth. Balchem also highlighted strategic investments in marketing partnerships, clinical research, and sustainability goals, while maintaining a focus on capital deployment through organic growth, M&A, debt reduction, and consistent dividend increases.
Balchem (BCPC) appoints Erin Gilson as new Chief Accounting Officer
Balchem Corporation has announced the appointment of Erin L. Gilson as Vice President and Chief Accounting Officer, effective April 1, 2026. She will succeed William A. Backus, who is retiring on March 31, 2026. Gilson has been with Balchem since 2016, previously serving as Senior Director of Accounting and Financial Reporting, and no material changes to her compensation are expected with this promotion.
Balchem Achieves Double-Digit Growth in GAAP Net Earnings for Q4 2025
Balchem Corporation reported record financial results for Q4 and full fiscal year 2025, with net sales rising 9.8% year-over-year and full-year revenue surpassing $1 billion. GAAP net earnings increased by 16.8% for the quarter and 20.5% for the full year, driven by strong performance across its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. The company also announced a 10% increase in its annual dividend, expressing optimism for continued growth in 2026.
Balchem (BCPC) Q4 2025 Earnings Call Transcript
Balchem Corporation reported record financial results for Q4 and full-year 2025, exceeding $1 billion in annual sales driven by strong performance across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The company discussed strategic initiatives including international expansion, significant investments in clinical research, and marketing partnerships, while highlighting sustainability achievements and a strong financial position with record free cash flow and a low leverage ratio. Management also addressed the Supreme Court ruling on tariffs and detailed their capital allocation priorities focused on organic growth, M&A, and shareholder returns.
Earnings call transcript: Balchem Q4 2025 earnings beat forecasts
Balchem Corporation reported strong financial results for Q4 2025, exceeding EPS and revenue forecasts, which pushed their sales over $1 billion for the first time. Despite the positive earnings, the company's stock declined in pre-market trading, possibly due to profit-taking or high earnings multiples. Balchem highlighted strategic international expansion and continued investment in research and marketing through partnerships like those with the New York Jets and Bayern Munich women's soccer team, while maintaining a strong financial position with low leverage.
Balchem Shares Hit 52-Week High as Q4 Earnings Beat Estimates on Strong Nutrition Demand
Balchem Corporation (BCPC) shares reached a new 52-week high after reporting strong fourth-quarter earnings and revenue that surpassed analyst expectations. The company's net sales increased by 9.8% to $263.6 million, and adjusted earnings per share rose to $1.31, driven by growth across all segments, especially Human Nutrition and Health. Balchem also achieved a record $1.037 billion in net sales for the full year 2025, marking its first time exceeding the billion-dollar annual revenue threshold.
Balchem boosts dividend after record $173.6M free cash flow in 2025
Balchem Corporation reported strong financial results for Q4 and full-year 2025, with record net sales of $1.037 billion and record adjusted EBITDA of $274.9 million. The company also achieved a record $173.6 million in free cash flow, leading to a double-digit percentage increase in its dividend. Despite the positive results, the stock BCPC declined by 2.11% on the day the news was published.
Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Balchem Corporation announced record financial results for both the fourth quarter and full year ended December 31, 2025. The company reported significant increases in net sales, net earnings, adjusted EBITDA, and free cash flow across all three of its segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. CEO Ted Harris attributed this growth to focused growth platforms and alignment with favorable "better for you" trends, expressing optimism for continued above-market growth in 2026 and beyond.
